127 related articles for article (PubMed ID: 11796990)
1. One step forwards, one step back.
Lifson JD; Martin MA
Nature; 2002 Jan; 415(6869):272-3. PubMed ID: 11796990
[No Abstract] [Full Text] [Related]
2. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
[TBL] [Abstract][Full Text] [Related]
3. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
4. Rates of HIV immune escape and reversion: implications for vaccination.
Davenport MP; Loh L; Petravic J; Kent SJ
Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
[TBL] [Abstract][Full Text] [Related]
5. HIV escape: there and back again.
Altman JD; Feinberg MB
Nat Med; 2004 Mar; 10(3):229-30. PubMed ID: 14991039
[No Abstract] [Full Text] [Related]
6. AIDS vaccine models: challenging challenge viruses.
Feinberg MB; Moore JP
Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
[No Abstract] [Full Text] [Related]
7. HIV CTL escape: at what cost?
Smith SM
Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
[TBL] [Abstract][Full Text] [Related]
8. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
9. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
Yang OO
Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
[No Abstract] [Full Text] [Related]
10. Developing DNA vaccines against immunodeficiency viruses.
Lu S
Curr Top Microbiol Immunol; 1998; 226():161-73. PubMed ID: 9479841
[No Abstract] [Full Text] [Related]
11. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
12. AIDS 1995. Vaccines and immunology: overview.
Montelaro RC; Wigzell H
AIDS; 1995; 9 Suppl A():S111-2. PubMed ID: 8819577
[No Abstract] [Full Text] [Related]
13. HIV vaccine development: perspective.
Bolognesi DP
Biotechnol Ther; 1991; 2(1-2):205-11. PubMed ID: 1845122
[No Abstract] [Full Text] [Related]
14. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes.
Yang OO
AIDS; 2008 Jan; 22(3):325-31. PubMed ID: 18195558
[No Abstract] [Full Text] [Related]
15. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
Hinkula J
Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
[TBL] [Abstract][Full Text] [Related]
16. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
17. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
Egan MA
Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
[No Abstract] [Full Text] [Related]
18. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
Kent SJ; Fernandez CS; Dale CJ; Davenport MP
Trends Microbiol; 2005 Jun; 13(6):243-6. PubMed ID: 15936652
[TBL] [Abstract][Full Text] [Related]
19. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
[TBL] [Abstract][Full Text] [Related]
20. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Emini EA; Koff WC
Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
